BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32898989)

  • 1. 68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist.
    Wang L; Yu F; Yang L; Zang S; Xue H; Yin X; Guo H; Sun H; Wang F
    Medicine (Baltimore); 2020 Sep; 99(36):e20755. PubMed ID: 32898989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUVmax/ADC Ratio as a Molecular Imaging Biomarker for Diagnosis of Biopsy-Naïve Primary Prostate Cancer.
    Chinnappan S; Chandra P; Kumar JS; Chandran G; Nath S
    Indian J Nucl Med; 2021; 36(4):377-384. PubMed ID: 35125755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 5. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical Validation of PSMA Expression Measured by
    Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
    J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of integrated
    Zeng Y; Leng X; Liao H; Jiang G; Chen P
    Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid imaging with [
    Glemser PA; Rotkopf LT; Ziener CH; Beuthien-Baumann B; Weru V; Kopp-Schneider A; Schlemmer HP; Dimitrakopoulou-Strauss A; Sachpekidis C
    Cancer Imaging; 2022 Sep; 22(1):53. PubMed ID: 36138437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of
    Gao J; Zhang C; Zhang Q; Fu Y; Zhao X; Chen M; Zhang B; Li D; Shi J; Wang F; Guo H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1531-1541. PubMed ID: 31025048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of
    Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective comparative study of [
    Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
    Lv J; Yu H; Yin H; Shi Y; Shi H
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
    Domachevsky L; Goldberg N; Bernstine H; Nidam M; Groshar D
    Eur Radiol; 2018 Dec; 28(12):5275-5283. PubMed ID: 29846803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the value of
    Luo L; Zheng A; Chang R; Li Y; Gao J; Wang Z; Duan X
    Cancer Imaging; 2023 Nov; 23(1):108. PubMed ID: 37924154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Utility of
    Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
    Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of
    Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
    Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.